AMN Healthcare Services, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMN research report →
Range $34.5 – $43
Price Chart
About the company
AMN Healthcare Services, Inc. (AMN) specializes in delivering comprehensive workforce solutions and staffing services to hospitals and healthcare facilities throughout the United States. Its operations are structured across three primary segments: The Nurse and Allied Solutions segment focuses on placing registered nurses in travel assignments, rapid response roles during emergencies or labor disruptions, and local positions.
- CEO
- Caroline Sullivan Grace
- IPO
- 2001
- Employees
- 2,664
- HQ
- Dallas, TX, US
Get TickerSpark's AI analysis on AMN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.38B
- P/E
- 12.49
- Fwd P/E
- 8.52
- PEG
- 0.01
- P/S
- 0.38
- P/B
- 1.76
- EV/EBITDA
- 5.36
- Div Yield
- 0.00%
- Gross Margin
- 28.40%
- Op Margin
- 5.76%
- Net Margin
- 3.10%
- ROE
- 15.19%
- ROIC
- 8.02%
Latest fiscal year · YoY change
- Revenue
- $2.73B-8.5%
- Gross Profit
- $774.06M-15.8%
- Op Income
- $33.17M
- Net Income
- $-95,702,000+34.9%
- EPS
- $-2.48+35.6%
- OCF Growth
- -15.9%
- FCF Growth
- -2.4%
- 52W High
- $49.62
- 52W Low
- $14.97
- 50D MA
- $38.91
- 200D MA
- $29.85
- Beta
- 0.43
- RSI (14)
- 35
- Avg Volume
- 761.45K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AMN Healthcare posted a strong third quarter on better-than-expected travel nurse/allied volume and a large labor-disruption reserve adjustment, while guiding Q4 revenue and margins lower as that disruption revenue rolls off.· November 5, 2026
- Q3 revenue was $717 million, up 13% year over year, with net income of $33 million and adjusted EPS of $1.16.
- Reported gross margin was 31.9% and adjusted EBITDA was $94 million, both boosted by a $51 million favorable reserve adjustment tied to prior labor-disruption events.
- Nurse and Allied revenue reached $460 million, up 15% excluding labor-disruption activity; travel nurse volume rose 21% and allied volume 12%.
- Management said five businesses have returned to year-over-year growth and sees a path for the remaining businesses to return to growth in 2027.
- Q4 guidance assumes a sharp step-down in labor-disruption revenue to $5 million versus $124 million a year ago, pressuring consolidated revenue and margins.
Third-quarter consolidated revenue was $717 million, up 13% year over year and 7% sequentially. Net income was $33 million, or $0.83 per share, versus $29 million last year, and adjusted EPS was $1.16. Adjusted EBITDA was $94 million, or 13% of revenue. Reported gross margin was 31.9%, which management said was 440 basis points above the top end of guidance, helped by a $51 million favorable reserve adjustment related to prior labor-disruption events. Nurse and Allied revenue was $460 million with 30.9% gross margin and 17.5% segment operating margin; Physician and Leadership revenue was $171 million; Locum Tenens revenue was $138 million; and Technology and Workforce Solutions revenue was $86 million. For Q4, AMN expects consolidated revenue of $655 million to $670 million, gross margin of 25.7% to 26.2%, operating margin of minus 0.1% to 0.5%, and adjusted EBITDA margin of 5.8% to 6.3%. Q4 guidance includes $5 million of labor-disruption revenue versus $124 million in Q4 2025. Excluding labor disruption, Nurse and Allied revenue is expected to grow 13% to 15% year over year, while Physician and Leadership is projected down 5% to 7% year over year and international nurse placements are expected to decline sequentially until embassy visa appointments normalize.
The CEO said AMN is benefiting from broader workforce-management demand, as clients increasingly want visibility into demand, supply, and performance across their labor force rather than just fill rates. She highlighted strong execution in Nurse and Allied, saying the team is now on track for its highest productivity levels ever, and pointed to companywide technology and process improvements as a key driver. Her tone was constructive but cautious: she sees momentum in core staffing and search, but also flagged near-term international headwinds from visa appointment delays and ongoing pricing competition in staffing.
The CFO emphasized that Q3 upside came from both stronger-than-expected operating performance and higher labor-disruption revenue than planned. He said reported gross margin of 31.9% was well above guidance because of the reserve adjustment, which added 25 basis points to gross margin, and noted an extra nearly $3 million workers’ compensation adjustment that also weighed on EBITDA. He also provided balance-sheet detail: cash and equivalents were $256 million, cash flow from operations was a use of $88 million in Q3, year-to-date operating cash flow was $285 million, total debt was $750 million, and leverage was 1.3x under the credit agreement. On the outlook, he framed Q4 as a lower-margin period because of the labor-disruption roll-off, international nurse slowdown, and seasonal effects, but said the company expects some margin recovery later as language-services and other businesses improve.
Analysts focused on the sustainability of travel nurse growth, the international nurse slowdown, Kaiser’s contract renewal, and whether 2027 could be a margin-recovery year. Management said travel nurse gains reflected both broader market demand and better fill rates across channels, not just market share, and said rates are still stable but could firm if demand continues to outpace supply. On international, management said embassy appointment delays are the main issue, expects a smaller step-down from Q4 to Q1, and thinks improvement later in 2027 is possible but hard to time. On Kaiser, management said the contract runs through end-2026 and they feel well positioned in the RFP. On locums and VMS, they described ongoing process and technology changes aimed at faster fill times and better execution, with benefits expected to build through 2027.
The call showed meaningful underlying demand recovery in Nurse and Allied, with travel nurse volume up 21% and allied up 12%, while management said fill rates improved across all channels. AMN also said five businesses are already back to year-over-year growth and several more could return in 2027 as process and technology initiatives mature. Management sounded optimistic that tighter labor supply, broader client interest in MSP/Total Talent Solutions, and eventual rate improvement could support higher growth and margins over time.
Near-term results are still being distorted by labor-disruption revenue, which will fall sharply in Q4, creating a big year-over-year decline and lower margins. International nurse placements face a near-term slowdown because embassy visa appointments have been “virtually nonexistent,” and management expects that to constrain placements into 2027 unless access improves. Pricing pressure remains an issue in language services and staffing remains competitive, with management acknowledging that bill rates have been stable for 18 months and that margin improvement may be gradual rather than immediate.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.0%
- Shares Outstanding
- 38.56M
- Float Shares
- 38.19M
of shares held by institutions
295 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AMN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Greg GianforteHouse · MT00 | Buy | Nov 9, 20 | Filing → |
| Greg GianforteHouse · MT00 | Buy | Aug 31, 20 | Filing → |
| Greg GianforteHouse · MT00 | Buy | Sep 2, 20 | Filing → |
| Greg GianforteHouse · MT00 | Buy | Jul 22, 20 | Filing → |
| Greg GianforteHouse · MT00 | Buy | Oct 11, 19 | Filing → |
| Greg GianforteHouse · MT00 | Sell | Sep 10, 19 | Filing → |
| Greg GianforteHouse · MT00 | Buy | Jan 24, 19 | Filing → |
| Greg GianforteHouse · MT00 | Sell | Dec 24, 18 | Filing → |
| Thomas Charles MacArthurHouse · NJ03 | Buy | Jun 7, 18 | Filing → |
| Greg GianforteHouse · MT00 | Buy | Jun 7, 18 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 7.08M | ▲ 438.98K |
| Vanguard Group Inc | 3.63M | ▼ 753.43K |
| Morgan Stanley | 1.98M | ▼ 305.34K |
| State Street Corp | 1.72M | ▲ 29.90K |
| Vanguard Capital Management LLC | 1.71M | ▼ 10.59K |
| Dimensional Fund Advisors LP | 1.70M | ▲ 416.23K |
| Arrowstreet Capital, Limited Partnership | 1.50M | ▲ 111.31K |
| Acadian Asset Management LLC | 1.42M | ▲ 390.03K |
| Allianz Asset Management Gmbh | 1.40M | ▲ 141.94K |
| Vanguard Portfolio Management LLC | 1.31M | ▲ 18.17K |
| Boston Partners | 1.18M | ▼ 493.04K |
| Two Sigma Investments, LP | 1.16M | ▼ 429.42K |
Held by 365 ETFs
Biggest fund positions in AMN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 15, 26 | Hagan Mark Christopher | other | 9,331 |
| Oct 15, 26 | Hagan Mark Christopher | other | 3,348 |
| Oct 15, 26 | Hagan Mark Christopher | other | 9,331 |
| Oct 15, 26 | Laughlin Whitney M | other | 4,976 |
| Oct 15, 26 | Laughlin Whitney M | other | 1,212 |
| Oct 15, 26 | Laughlin Whitney M | other | 4,976 |
| Sep 15, 26 | Laughlin Whitney M | other | 498 |
| Sep 15, 26 | Laughlin Whitney M | other | 122 |
| Sep 15, 26 | Laughlin Whitney M | other | 498 |
| May 1, 26 | Jones Daphne E | other | 8,325 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AMN coverage
Recent articles, reports, and earnings notes.
No research on AMN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMN report →Here's Why AMN Healthcare Services (AMN) is a Strong Value Stock
zacks.com · Nov 16
Here's Why You Should Retain AMN Stock in Your Portfolio for Now
zacks.com · Nov 12
AMN Healthcare (AMN) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Nov 9
AMN Healthcare Services Q3 Earnings Call Highlights
marketbeat.com · Nov 6
AMN Healthcare Services, Inc. (AMN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
AMN Healthcare (AMN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Nov 5
AMN HEALTHCARE ANNOUNCES THIRD QUARTER 2026 RESULTS
prnewswire.com · Nov 5
Why AMN Healthcare Services (AMN) is a Top Value Stock for the Long-Term
zacks.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.